Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LataMed AILMEDD +10.57%26 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates LMEDD with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 2,820 Software companies, LataMed AI ranks worse than 35460.96% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. LataMed AI's EBITDA for the
three
months ended in Mar. 2026 was $-0.04 Mil. LataMed AI's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, LataMed AI's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
LataMed AI (OTCPK:LMEDD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
LataMed AI EBITDA Margin % Related Terms
LataMed AI EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for LataMed AI's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LMEDD vs KLTR, BZAI, THRY: EBITDA Margin % Comparison
For the Software - Application subindustry, LataMed AI's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LataMed AI EBITDA Margin % vs Software Industry
For the Software industry and Technology sector, LataMed AI's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where LataMed AI's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LataMed AI (LMEDD) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LataMed AI and its competitors. According to the industry distribution chart, LataMed AI ranks #999999 out of 2820 companies in the Software industry.
Is LataMed AI's EBITDA Margin % too high?
LataMed AI's current EBITDA Margin % is 0.00%. Based on the distribution chart, LataMed AI ranks #999999 out of 2820 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, LataMed AI has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does LataMed AI's EBITDA Margin % compare to KLTR and BZAI?
According to the Software industry distribution chart, LataMed AI ranks #999999 out of 2820 companies for EBITDA Margin %. This places LataMed AI in the lower half of its industry. The industry median EBITDA Margin % is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Software company?
The median EBITDA Margin % among Software companies is 8.10, based on 2,820 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LataMed AI and its competitors. For the Software industry, the median EBITDA Margin % is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LataMed AI's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LataMed AI stock overvalued right now?
LataMed AI (LMEDD) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. LataMed AI's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For LataMed AI (LMEDD), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LataMed AI Corp is a technology company focused on the development and deployment of artificial intelligence-driven healthcare solutions across Latin America. Its healthcare platform includes AI-enabled analytics, telehealth infrastructure, and coordinated care systems designed to support healthcare delivery in emerging markets. The company develops digital infrastructure for patient prioritization, clinical workflow management, telehealth access, care coordination, and healthcare system operations. It holds issued patents for its core AI modules-CardioAI, PulmoAI, and NeuroAI-which deliver predictive analytics for cardiovascular, pulmonary, and neurological disease detection and management.
26GF Score
Get the complete analysis for LMEDD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMEDD has been successfully added to your 
